Shares of Aptinyx Inc (NASDAQ:APTX) have received a consensus recommendation of “Buy” from the nine research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $13.67.
APTX has been the topic of a number of research reports. ValuEngine upgraded Aptinyx from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research cut Aptinyx from a “buy” rating to a “hold” rating in a report on Tuesday, October 15th. JPMorgan Chase & Co. cut Aptinyx from a “neutral” rating to an “underweight” rating in a report on Tuesday, August 13th. Finally, Wedbush initiated coverage on Aptinyx in a report on Thursday, September 12th. They issued an “outperform” rating and a $7.00 price target on the stock.
APTX opened at $3.08 on Wednesday. The stock has a market cap of $101.02 million and a P/E ratio of -1.17. The stock’s 50 day simple moving average is $3.49 and its 200 day simple moving average is $3.51. Aptinyx has a 1-year low of $2.61 and a 1-year high of $27.36.
Large investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Aptinyx during the 2nd quarter valued at $49,000. Gabelli Funds LLC grew its holdings in Aptinyx by 45.9% during the 2nd quarter. Gabelli Funds LLC now owns 15,901 shares of the company’s stock valued at $53,000 after buying an additional 5,000 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Aptinyx during the 2nd quarter valued at $54,000. Weiss Asset Management LP acquired a new stake in Aptinyx during the 2nd quarter valued at $65,000. Finally, A.R.T. Advisors LLC grew its holdings in Aptinyx by 15.9% during the 2nd quarter. A.R.T. Advisors LLC now owns 27,000 shares of the company’s stock valued at $90,000 after buying an additional 3,695 shares during the last quarter. Hedge funds and other institutional investors own 53.09% of the company’s stock.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
See Also: What is Liquidity?
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.